StockData
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc (XFOR) company profile

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$3.09+0.26 (+9.19%)

Close on Nov 17, 2026Market cap $306.36MP/E –Yield –

About X4 Pharmaceuticals

Biological Products, (No Diagnostic Substances), SIC 2836

The company is a biopharmaceutical business dedicated to creating and commercializing targeted therapies for rare hematological disorders. Its core asset is mavorixafor, an orally administered CXCR4 chemokine receptor antagonist formulated as a capsule. The company markets XOLREMDI (mavorixafor), an FDA-approved prescription medicine for patients aged twelve and older with WHIM syndrome, an ultra-rare primary immunodeficiency and neutropenic condition. In addition to commercializing this therapy, the enterprise is conducting a global Phase 3 clinical trial evaluating mavorixafor for individuals suffering from chronic neutropenia.

The company distributes its approved treatment to patients within the United States through a specialty pharmacy and collaborates with regional partners across international territories, including Europe, the Middle East, North Africa, Australia, New Zealand, and parts of East Asia. Its corporate operations rely on external contract manufacturing organizations, with clinical trials encompassing over one hundred active testing sites internationally, including approximately twenty centers in the United States. The excerpt does not provide the city, state, or country of its headquarters.

Summary of the business section of X4 Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
X4 Pharmaceuticals, Inc
Headquarters
Boston, MA
Address
61 North Beacon Street, 4th Floor 02134
Phone
(857) 529-8300
Employees
45, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts, US

Stock & identifiers

Ticker
XFOR
Former tickers
ASNS until May 15, 2019
Exchange
Nasdaq
IPO date
Nov 16, 2017
Shares outstanding
99M, Jul 31, 2026
Public float
$14.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-30 reverse, Apr 28, 2025; 1-for-31 reverse, May 15, 2019; 1-for-6 reverse, Mar 14, 2019
SEC CIK
1501697
CUSIP
98420X202
ISIN
US98420X2027
FIGI
BBG001J1CYH8
Share class FIGI
BBG001TCY1B7
LEI
549300R0UFVPXWP86U94
EIN
27-3181608

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Adam R. CraigExecutive Chairman, Director333,251
Paula RaganPresident and CEO, Director3,337,386
David KirskeChief Financial Officer155,983
John VolponePresident265,305
Natasha Fay ThorenChief Legal Officer9,462
Mark BaldryChief Commercial Officer25,337
Mary DiBiaseChief Operating Officer1,140,980
Adam S. MostafaChief Financial Officer850,000
Christophe Arbet-EngelsChief Medical Officer864,207
Kelly GoldDirector–
Gary BridgerDirector4,722
Murray StewartDirector7,883
Michael S. WyzgaDirector5,555
Craecker Francoise deDirector4,722
David W. J. McGirrDirector4,722
Keith WoodsDirector6,000

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
CRAIG
$6.71M$16.32M$5.63M$13–
FY2025
RAGAN
$2.64M$545.38K$5.63M$13–
FY2024
CRAIG
$0$0$1.24M$74–
FY2024
RAGAN
$2.15M$1.43M$1.24M$74–
FY2023
CRAIG
$0$0$1.39M$84–
FY2023
RAGAN
$2.04M$1.29M$1.39M$84–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Adam R. Craig, M.D., Ph.D., M.B.A.
Executive Chairman
$179.63K––$6.41M$114.48K$139$6.71M–
Paula Ragan, Ph.D.
Former President and Chief Executive Officer
$420.17K–$1.08M––$1.14M$2.64M+23%
John Volpone, M.B.A.
President and Chief Operating Officer
$176.54K––$6.41M$75.01K$4.99K$6.67M–
David Kirske
Chief Financial Officer, Treasurer and Corporate Secretary
$194.19K$120.00K–$4.18M$103.13K$901$4.60M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 45 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?